HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for shares of HUTCHMED in a research report issued on Monday, June 6th. Cantor Fitzgerald analyst L. Chen forecasts that the company will earn ($1.20) per share for the year.
A number of other analysts have also recently issued reports on the company. Zacks Investment Research cut HUTCHMED from a “buy” rating to a “hold” rating in a research report on Thursday, May 5th. Deutsche Bank Aktiengesellschaft cut HUTCHMED from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, StockNews.com assumed coverage on HUTCHMED in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, HUTCHMED presently has a consensus rating of “Hold” and a consensus target price of $39.50.
Several institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in shares of HUTCHMED by 12.7% during the third quarter. Geode Capital Management LLC now owns 346,503 shares of the company’s stock worth $12,589,000 after buying an additional 39,025 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of HUTCHMED by 56.5% during the fourth quarter. BNP Paribas Arbitrage SA now owns 230,558 shares of the company’s stock worth $8,088,000 after buying an additional 83,265 shares in the last quarter. Capital International Investors grew its holdings in shares of HUTCHMED by 1.4% during the fourth quarter. Capital International Investors now owns 9,054,891 shares of the company’s stock worth $317,923,000 after buying an additional 128,422 shares in the last quarter. Schroder Investment Management Group grew its holdings in shares of HUTCHMED by 2.4% during the fourth quarter. Schroder Investment Management Group now owns 3,102,043 shares of the company’s stock worth $21,764,000 after buying an additional 71,992 shares in the last quarter. Finally, Royal London Asset Management Ltd. grew its holdings in shares of HUTCHMED by 7.1% during the fourth quarter. Royal London Asset Management Ltd. now owns 134,900 shares of the company’s stock worth $4,724,000 after buying an additional 8,900 shares in the last quarter. Institutional investors own 31.03% of the company’s stock.
HUTCHMED Company Profile (Get Rating)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- Heavy Buying Points to Upside for These 3 Stocks
- 3 Intriguing Stocks With Sub-10 P/E Ratios
- Snap Inc: Revised Guidance & Steeping Losses
- Time to Buy Take-Two Interactive Stock
- 3 Software Plays Showing Signs of Recovery
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.